Protocol for EpiCom: A phase 3b/4 study of behavioral outcomes following adjunctive cannabidiol for the management of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND)
PLoS One. 2025 Jun 12;20(6):e0324648. doi: 10.1371/journal.pone.0324648. eCollection 2025. ABSTRACT Tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND) affect ≈90% of individuals with TSC and significantly …